The TRANSCEND CLL 004 clinical trial also combined ibrutinib with the anti-CD19 CAR T cell product lisocabtagene maraleucel for the treatment of r/r CLL/SLL patients [98]. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.